Sarcopenia in Older Patients in the Acute Hospital Setting
This study tests whether a Virtual Gate Device (VGD) can help prevent muscle loss in older adults during hospital stays. Muscle loss, called sarcopenia, commonly occurs when patients are immobilized in the hospital, and this technology aims to minimize that decline.
Key Objective: The trial is testing whether using the Virtual Gate Device can prevent or reduce hospital-acquired muscle loss caused by immobilization in older patients.
Who to Consider: Older adults who are hospitalized and at risk for muscle loss from bed rest or limited mobility should consider enrolling in this study.
Trial Parameters
Brief Summary
This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.
Eligibility Criteria
Inclusion Criteria: * Male and female patients 75 years of age and older. * Patients admitted with an acute infection (clinically from a respiratory or urinary source). * Expected length of hospitalization of at least 4 days. * Patients who are conscious and cognitively able to provide written informed consent as determined by a score of 0 on the 4AT scale Exclusion Criteria: * Male and female patients under 75 years of age. * Expected length of hospitalization of less than 4 days. * A condition limiting the use of the virtual gate device (VGD) due to factors relating to discomfort or safety, including but not limited to: fracture, amputation, local infection, pain, paralysis of one or both lower limbs, cardiac arrhythmia or cardiac pacemaker. * Patients who are unable to or do not provide informed consent for participation. * A score 1 or more on the 4AT scale.